Name (Synonyms) | Correlation | |
---|---|---|
drug995 | Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet Wiki | 1.00 |
drug2122 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D014456 | Ulcer NIH | 0.41 |
D003092 | Colitis NIH | 0.41 |
D003093 | Colitis, Ulcerative NIH | 0.41 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002583 | Colitis HPO | 0.41 |
HP:0100279 | Ulcerative colitis HPO | 0.41 |
There is one clinical trial.
This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not responded at the end of the induction period in Study M14-234 Substudy 1, who have had loss of response during the maintenance period of Study M14-234 Substudy 3, or who have successfully completed Study M14-234 Substudy 3.
Description: Treatment-emergent adverse events are defined as events that begin or worsen either on or after the first dose of the study drug and within 30 days after the last dose of the study drug in the analysis period.
Measure: Assessing Treatment-Emergent Adverse Events Time: Up to 288 Weeks